Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).
Authors
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Therese Karlsson (ORCID: https://orcid.org/0000-0002-8558-8338)
- Sean Wharton (ORCID: https://orcid.org/0000-0003-0111-1530)
- W. Timothy Garvey (ORCID: https://orcid.org/0000-0003-0822-0860)
- Ruben Vale (ORCID: https://orcid.org/0000-0002-6640-1945)
- Domenica Rubino (ORCID: https://orcid.org/0000-0002-3072-2819)
- Paweł Bogdański (ORCID: https://orcid.org/0000-0002-0563-1624)
- Stephan Jacob (ORCID: https://orcid.org/0000-0002-4954-1145)
- Chaithra Shaji
Institutions
- Poznan University of Medical Sciences (PL)
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- York University (CA)
- University of Alabama at Birmingham (US)
- Southwestern Medical Center (US)
- Nephrologisches Zentrum Villingen-Schwenningen (DE)
- START Clinic (CA)
- Washington Center for Weight Management and Research (US)
- Novo Nordisk (India) (IN)
- The University of Texas Southwestern Medical Center (US)
- McMaster University (CA)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1056/nejmoa2500969
- Citations
- 33
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 42.73